---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-007862"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T02:08:48.054465+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Senti Biosciences appoints Feng Hsiung to board, stockholders approve 4.3M share increase in equity plan

## Summary
- Feng Hsiung appointed to board as Class III director effective March 7, 2025; also joins audit committee.
- Stockholders approved Amended 2022 Equity Incentive Plan adding 4,300,000 shares and extending term to 2035.
- Board adopted Amended Inducement Plan reserving extra 500,000 shares for new-hire inducement grants.
- Non-employee director compensation policy revised; each continuing director received 43,900-share option grant.
- CEO Timothy Lu received contingent option for 1,927,073 shares and RSU for 642,358 shares.

## SEC filing metadata
- accession: 0001140361-25-007862
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000114036125007862/0001140361-25-007862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000114036125007862/ef20045153_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-007862
- JSON: https://secwatch.observer/filing/0001140361-25-007862.json
- Plain text: https://secwatch.observer/filing/0001140361-25-007862.txt

## Key facts
- Executive change
  Feng Hsiung was appointed as Class III Director at Senti Biosciences, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On March 7, 2025, the Board of Directors (the “Board”) of Senti Biosciences, Inc. (the “Company”) approved the appointment of Feng Hsiung to the Board, pursuant to the terms of a letter agreement dated as of December 2, 2024, by and between the Company and Celadon Partners SPV 24.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000114036125007862/0001140361-25-007862-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.